senate Bill S1306A

Requires that insurance companies provide coverage for surveillance tests for ovarian cancer of certain insured individuals

download pdf

Sponsor

Bill Status


  • Introduced
  • In Committee
  • On Floor Calendar
    • Passed Senate
    • Passed Assembly
  • Delivered to Governor
  • Signed/Vetoed by Governor
view actions

actions

  • 09 / Jan / 2013
    • REFERRED TO INSURANCE
  • 08 / Jan / 2014
    • REFERRED TO INSURANCE
  • 21 / Jan / 2014
    • AMEND AND RECOMMIT TO INSURANCE
  • 21 / Jan / 2014
    • PRINT NUMBER 1306A

Summary

Requires that insurance companies provide coverage for surveillance tests for ovarian cancer of insured individuals who are deemed to be at risk for ovarian cancer.

do you support this bill?

Bill Details

Versions:
S1306
S1306A
Legislative Cycle:
2013-2014
Current Committee:
Senate Insurance
Law Section:
Insurance Law
Laws Affected:
Amd ยงยง3216, 3221 & 4303, Ins L
Versions Introduced in Previous Legislative Cycles:
2011-2012: S6604
2009-2010: A6475
2007-2008: A5931

Sponsor Memo

BILL NUMBER:S1306A

TITLE OF BILL: An act to amend the insurance law, in relation to
providing coverage for surveillance tests for ovarian cancer

PURPOSE OR GENERAL IDEA OF BILL: To require insurers to cover
surveillance tests for ovarian cancer for female insureds who are at
risk for this type of cancer

SUMMARY OF SPECIFIC PROVISIONS: Subsection (i) of section 3216 of the
insurance law is amended. Subsection (k) of section 3221 of the
insurance law is amended by adding a new paragraph 19.

Section 4303 of the insurance law is amended by adding a new
subsection (oo).

The amendments provide that every policy that provides medical, major
medical or similar comprehensive type coverage shall provide coverage
for surveillance tests for ovarian cancer for an insured who is at
risk for ovarian cancer. An insured is deemed to be at risk if: she
has a family history of one or more first degree relatives with
ovarian cancer; three or more female relatives with breast cancer or
non-polyposis colorectal cancer; she texts positive for BRCA 1 or BRCA
2 mutations. Surveillance tests for ovarian cancer shall mean annual
screening for ovarian cancer using: CA-125 serum tumor maker testing;
transvaginal ultrasound; and pelvic examination.

JUSTIFICATION: Ovarian cancer gives no warning signs and is very
difficult to detect. Early detection through surveillance tests and
treatment are the keys to stopping this deadly disease.

PRIOR LEGISLATIVE HISTORY: This bill was introduced in previous
legislative sessions. 2011/2012 - S.6604 - Referred to Insurance

FISCAL IMPLICATION FOR STATE AND LOCAL GOVERNMENTS: Minimal.

EFFECTIVE DATE: This act shall take effect immediately and shall
apply to any policy issued, renewed, or modified after such effective
date.

view bill text
                    S T A T E   O F   N E W   Y O R K
________________________________________________________________________

                                 1306--A

                       2013-2014 Regular Sessions

                            I N  S E N A T E

                               (PREFILED)

                             January 9, 2013
                               ___________

Introduced  by Sen. STAVISKY -- read twice and ordered printed, and when
  printed to be committed to the Committee on Insurance  --  recommitted
  to the Committee on Insurance in accordance with Senate Rule 6, sec. 8
  --  committee  discharged,  bill amended, ordered reprinted as amended
  and recommitted to said committee

AN ACT to amend the insurance law, in relation to providing coverage for
  surveillance tests for ovarian cancer

  THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
BLY, DO ENACT AS FOLLOWS:

  Section  1.  Subsection  (i)  of  section 3216 of the insurance law is
amended by adding a new paragraph 30 to read as follows:
  (30) EVERY POLICY THAT  PROVIDES  MEDICAL,  MAJOR-MEDICAL  OR  SIMILAR
COMPREHENSIVE-TYPE  COVERAGE  SHALL  PROVIDE  COVERAGE  FOR SURVEILLANCE
TESTS FOR OVARIAN CANCER FOR AN INSURED  WHO  IS  AT  RISK  FOR  OVARIAN
CANCER.  (A) FOR PURPOSES OF THIS SUBSECTION, AN INSURED IS DEEMED TO BE
AT RISK IF:
  (I) SHE HAS A FAMILY HISTORY OF:
  1. ONE OR MORE FIRST-DEGREE RELATIVE WITH OVARIAN CANCER;
  2. THREE OR MORE FEMALE RELATIVES WITH BREAST CANCER; OR
  3. NONPOLYPOSIS COLORECTAL CANCER; OR
  (II) SHE TESTS POSITIVE FOR BRCA1 OR BRCA2 MUTATIONS.
  (B) FOR PURPOSES OF THIS SUBSECTION, SURVEILLANCE  TESTS  FOR  OVARIAN
CANCER SHALL MEAN ANNUAL SCREENING FOR OVARIAN CANCER USING:
  (I) CA-125 SERUM TUMOR MARKER TESTING;
  (II) TRANSVAGINAL ULTRASOUND; AND
  (III) PELVIC EXAMINATION.
  S 2. Subsection (k) of section 3221 of the insurance law is amended by
adding a new paragraph 19 to read as follows:
  (19) EVERY GROUP OR BLANKET POLICY DELIVERED OR ISSUED FOR DELIVERY IN
THIS  STATE  WHICH PROVIDES HOSPITAL, SURGICAL OR MEDICAL COVERAGE SHALL

 EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                      [ ] is old law to be omitted.
                                                           LBD04283-02-4

S. 1306--A                          2

INCLUDE COVERAGE FOR  SURVEILLANCE  TESTS  FOR  OVARIAN  CANCER  FOR  AN
INSURED  WHO  IS  AT  RISK  FOR OVARIAN CANCER. (A) FOR PURPOSES OF THIS
SUBSECTION, AN INSURED IS DEEMED TO BE AT RISK IF:
  (I) SHE HAS A FAMILY HISTORY OF:
  1. ONE OR MORE FIRST-DEGREE RELATIVE WITH OVARIAN CANCER;
  2. THREE OR MORE FEMALE RELATIVES WITH BREAST CANCER; OR
  3. NONPOLYPOSIS COLORECTAL CANCER; OR
  (II) SHE TESTS POSITIVE FOR BRCA1 OR BRCA2 MUTATIONS.
  (B)  FOR  PURPOSES  OF THIS SUBSECTION, SURVEILLANCE TESTS FOR OVARIAN
CANCER SHALL MEAN ANNUAL SCREENING FOR OVARIAN CANCER USING:
  (I) CA-125 SERUM TUMOR MARKER TESTING;
  (II) TRANSVAGINAL ULTRASOUND; AND
  (III) PELVIC EXAMINATION.
  S 3. Section 4303 of the insurance law is  amended  by  adding  a  new
subsection (oo) to read as follows:
  (OO)  A HEALTH SERVICE CORPORATION OR MEDICAL EXPENSE INDEMNITY CORPO-
RATION   WHICH    PROVIDES    MEDICAL,    MAJOR-MEDICAL    OR    SIMILAR
COMPREHENSIVE-TYPE COVERAGE MUST PROVIDE COVERAGE FOR SURVEILLANCE TESTS
FOR OVARIAN CANCER FOR AN INSURED WHO IS AT RISK FOR OVARIAN CANCER. (1)
FOR PURPOSES OF THIS SUBSECTION, AN INSURED IS DEEMED TO BE AT RISK IF:
  (A) SHE HAS A FAMILY HISTORY OF:
  (I) ONE OR MORE FIRST-DEGREE RELATIVE WITH OVARIAN CANCER;
  (II) THREE OR MORE FEMALE RELATIVES WITH BREAST CANCER; OR
  (III) NONPOLYPOSIS COLORECTAL CANCER; OR
  (B) SHE TESTS POSITIVE FOR BRCA1 OR BRCA2 MUTATIONS.
  (2)  FOR  PURPOSES  OF THIS SUBSECTION, SURVEILLANCE TESTS FOR OVARIAN
CANCER SHALL MEAN ANNUAL SCREENING FOR OVARIAN CANCER USING:
  (A) CA-125 SERUM TUMOR MARKER TESTING;
  (B) TRANSVAGINAL ULTRASOUND; AND
  (C) PELVIC EXAMINATION.
  S 4. This act shall take effect immediately and  shall  apply  to  any
policy issued, renewed, or modified after such effective date.

Comments

Open Legislation comments facilitate discussion of New York State legislation. All comments are subject to moderation. Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity or hate speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Comment moderation is generally performed Monday through Friday.

By contributing or voting you agree to the Terms of Participation and verify you are over 13.